Celltrion unveiled the current operational status and future plans for its Branchburg facility on Thursday, aiming to dispel market concerns over recent signals from the Donald Trump administration about potential tariff policy changes.
The company finalized its acquisition of Eli Lilly’s Branchburg production facility late last year. By January’s end, Celltrion had completed a thorough facility inspection and preparations for operations.
This month, the company launched production of Lilly contract manufacturing organization (CMO) products across all lines, showcasing the efficiency of its local operations.
Alongside its biopharmaceutical CMO activities, Celltrion has begun validation procedures for manufacturing its own products. The firm aims to establish a system for supplying locally produced items to the U.S. market by integrating local production with its direct sales network.
As an immediate measure, Celltrion plans to maintain sales unaffected by tariffs using two years’ worth of inventory already in the U.S. until locally produced goods are ready for shipment.
Looking ahead, the company intends to operate a tariff-resistant production and sales system by directly supplying products from the Branchburg facility.
Despite the U.S. Supreme Court’s decision on mutual tariff invalidation and potential shifts in the Trump administration’s tariff policies, Celltrion appears to have completed a structural response to tariff risks by establishing a local production and supply base.
A Celltrion spokesperson stated that they’ve implemented all necessary measures to ensure the business operations remain unaffected, regardless of how U.S. tariff issues evolve. It will continue to closely monitor local market conditions and strive to protect shareholder value.